A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
|Articles|August 26, 2016
Biosimilar Naming Convention Debate Highlights Specialty Pharmacy Week in Review
Author(s)Davy James, Managing Editor
Top news of the week from Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/biosimilar-naming-convention-debate-highlights-spe" target="_blank">View the story "Biosimilar Naming Convention Debate Highlights Specialty Pharmacy Week in Review" on Storify</a>]
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
As pharmaceutical markets become increasingly dynamic, health systems may benefit from shifting toward unit-level economic frameworks that evaluate cost and margin performance.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5